Jason A. Okazaki Sells 1,569 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total value of $19,941.99. Following the completion of the sale, the chief executive officer now owns 16,423 shares of the company’s stock, valued at $208,736.33. The sale was disclosed in a filing with the SEC, which is available at this link.

Assembly Biosciences Stock Performance

Shares of ASMB stock traded up $0.80 during trading hours on Wednesday, hitting $13.27. 12,137 shares of the company were exchanged, compared to its average volume of 26,399. Assembly Biosciences, Inc. has a one year low of $7.69 and a one year high of $20.04. The business’s 50-day simple moving average is $13.13 and its two-hundred day simple moving average is $11.14. The stock has a market capitalization of $72.72 million, a price-to-earnings ratio of -0.78 and a beta of 0.57.

Hedge Funds Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Acuitas Investments LLC bought a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned about 0.40% of Assembly Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ASMB shares. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st. StockNews.com raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.